| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10044928 | HBV | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
| TVIS44029725 | HTLV-1 | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
| TVIS44051802 | HTLV-1 | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CYSLTR1 |
|---|---|
| DrugBank ID | DB00471 |
| Drug Name | Montelukast |
| Target ID | BE0000705 |
| UniProt ID | Q9Y271 |
| Regulation Type | antagonist |
| PubMed IDs | 15013935; 15456537; 16815057; 16815146; 17199874; 11752352; 23859232; 11739141; 29587204; 23801612; 18031150; 16630953 |
| Citations | Nayak A: A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother. 2004 Mar;5(3):679-86.@@Zhang YJ, Zhang L, Wang SB, Shen HH, Wei EQ: Montelukast modulates lung CysLT(1) receptor expression and eosinophilic inflammation in asthmatic mice. Acta Pharmacol Sin. 2004 Oct;25(10):1341-6.@@Hamacher J, Eichert K, Braun C, Grebe T, Strub A, Lucas R, Eltze M, Wendel A: Montelukast exerts no acute direct effect on NO synthases. Pulm Pharmacol Ther. 2007;20(5):525-33. Epub 2006 May 19.@@Langlois A, Ferland C, Tremblay GM, Laviolette M: Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006 Jul;118(1):113-9. Epub 2006 May 19.@@Alfieri AB, Tramontana M, Cialdai C, Lecci A, Giuliani S, Crea A, Manzini S, Maggi CA: Heterogeneous effect of leucotriene CysLT1 receptor antagonists on antigen-induced motor and inflammatory responses in guinea-pig airways. Auton Autacoid Pharmacol. 2007 Jan;27(1):39-46.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Singh RK, Tandon R, Dastidar SG, Ray A: A review on leukotrienes and their receptors with reference to asthma. J Asthma. 2013 Nov;50(9):922-31. doi: 10.3109/02770903.2013.823447. Epub 2013 Aug 16.@@Amrani Y, Moore PE, Hoffman R, Shore SA, Panettieri RA Jr: Interferon-gamma modulates cysteinyl leukotriene receptor-1 expression and function in human airway myocytes. Am J Respir Crit Care Med. 2001 Dec 1;164(11):2098-101. doi: 10.1164/ajrccm.164.11.2108005.@@Wei J, Chen S, Guo W, Feng B, Yang S, Huang C, Chu J: Leukotriene D4 induces cellular senescence in osteoblasts. Int Immunopharmacol. 2018 May;58:154-159. doi: 10.1016/j.intimp.2017.12.027. Epub 2018 Mar 26.@@Zhang Z, Luo J, Huang J, Liu Z, Fang S, Zhang WP, Wei E, Lu Y: [Leukotriene D4 activates BV2 microglia in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 May;42(3):253-60.@@Reques FG, Rodriguez JL: Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs. 1999 Jun;11(6):385-94. doi: 10.2165/00063030-199911060-00003.@@Lamoureux J, Stankova J, Rola-Pleszczynski M: Leukotriene D4 enhances immunoglobulin production in CD40-activated human B lymphocytes. J Allergy Clin Immunol. 2006 Apr;117(4):924-30. doi: 10.1016/j.jaci.2005.12.1329. Epub 2006 Feb 7. |
| Groups | Approved |
| Direct Classification | Linear 1,3-diarylpropanoids |
| SMILES | OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(C=CC2=NC3=C(C=CC(Cl)=C3)C=C2)=C1 |
| Pathways | |
| PharmGKB | PA450546 |
| ChEMBL | CHEMBL787 |
